Your firm did not notify the license holder ofa deviation that may potentially affect the quality of a distributed drug product.
Inspection Record
Medlmmune UK Limited (AstraZeneca/Supply Biologics) — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
The bacterial endotoxin procedure is deficient to ensure adequate detection of endotoxin in the samples.
Critical reagents are not always qualified prior to release for use in the manufacturing ofU.S.
There is a lack ofvalidation to support on assigned expiry.
A record as of the US FDA document published on 2026-10-30. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.